WHAT DOES THIS MEAN FOR PATIENTS? {#sec11}
=================================

The World Health Organization recognizes the inability to have a healthy child after 1 year of attempting pregnancy as a disease or a disability. The psychosocial implications of infertility are vast, including depression, discrimination, and ostracism, the latter being of particular importance in lower income countries.

Determining the prevalence and burden of infertility, as well as performing regular surveillance on ART treatments and outcomes, is essential to inform policy, conduct research, and counsel patients. For example, the International Committee for Monitoring Assisted Reproductive Technologies relies on large-population data from regional and national ART registries around the world. With these data, they are able to provide reports depicting trends in practice, utilization of health care, and pregnancy outcomes after treatment.

Accurate and robust data are paramount to providing such reports. While these reports are reliant on administrative databases, our systematic review demonstrated that the quality assurance practices to establish accurate and reliable data are lacking in the literature. Moreover, where reports were published, adherence to reporting guidelines for studies using administrative data was also insufficient. We have provided a comprehensive review of the current literature, describing current practices, various strategies, and guidelines for which a validation study should adhere to in order to ensure accurate data.

Introduction {#sec12}
============

Infertility burdens 1.9% to 10.5% of child-seeking women worldwide and was estimated to affect 48.5 million couples in 2010 ([@ref38]). According to the International Committee for Monitoring Assisted Reproductive Technologies (ICMART), 1.4 to 1.6 million ART cycles were initiated per year from 2008 to 2010, resulting in approximately 800 000 babies born over this time period ([@ref18]). ART is a rapidly evolving field in medicine with new advances in research and technology. From freezing techniques for gametes and embryos ([@ref36]; [@ref1]; [@ref43]) to the number of embryos replaced ([@ref47]; [@ref43]) and utilization of PGD ([@ref24]), reproductive technologies and guidelines are changing regularly. It is, therefore, prudent to ensure we can adequately monitor treatment outcomes and adverse events. Studies from the USA and Europe estimate that the prevalence of live births born after IVF ranges from 1% to 6% ([@ref60]; [@ref61]). The risk of adverse obstetrical events is significantly higher in ART compared to naturally conceived pregnancies ([@ref39]; [@ref53]; [@ref48]). However, the prevalence of these complications attributed to ART, such as ectopic pregnancies, placenta previa, and congenital anomalies, is low, with estimates 1--2% ([@ref45]; [@ref52]), 1.6% ([@ref49]), and \~8% ([@ref16]), respectively. Similarly, other neonatal outcomes, including small for gestational age, preterm delivery, and admission to a critical unit, also occur infrequently ([@ref39]; [@ref53]; [@ref48]). Therefore, in order to adequately understand the implications of such treatment, studies using large sample sizes are required.

Collections of routinely collected data, such as administrative databases and registries, are excellent sources of population-level data. These databases often contain sociodemographic information, health care utilization, treatment, and diagnostic information affiliated with health care visits. However, these data are not collected for a specific research question and are prone to error resulting from clerical errors, illegible charts, and documentation problems ([@ref27]). If not validated adequately, utilization of these data for surveillance, quality improvement, and research can lead to misclassification bias and unmeasured confounding due to missing data ([@ref5]).

Many studies that use large administrative and registry databases to identify patients who undergo ART treatments indicate that they are using validated data ([@ref19]; [@ref63]; [@ref17]). However, the literature is scarce on validation studies and measures performed to ensure accuracy among these databases. There is extensive literature indicating the importance of presenting measures of validity, including sensitivity, specificity, and positive predictive values (PPVs), to reflect whether these data can be reliably used for research and reporting ([@ref57]; [@ref26]; [@ref66]; [@ref4]).

Ideally, a validation study uses a gold standard as a measure to guide the accuracy and reliability of the validated variable. Based on the Standards for Reporting of Diagnostic Accuracy Studies guidelines for evaluating diagnostic tests, a gold standard should be the best available test in identifying the condition of interest ([@ref7]). To this end, the gold standard of determining accuracy of database variables or data elements has not been established ([@ref57]; [@ref30]; [@ref32]; [@ref5]). In the absence of a true gold standard, some argue that the medical record should serve as the reference standard ([@ref67]; [@ref20]).

With this in mind, we conducted a systematic review to identify the validation studies of databases that contain these routinely collected data (including administrative data and registry data) in an ART setting. Our primary objective was to assess how ART centers (either databases maintained by a clinic or those managed by a region or country) validate and report their fertility data, their rationale for choosing specific data elements for validation activities, the extent to which a database is considered valid for use, and actions taken when validity was deemed poor. Our secondary objective was to investigate whether ART centers were reporting their validation studies in accordance with the published reporting guidelines for validation studies ([@ref4]) with details pertaining to the method of validation and quality control, the variables chosen to validate the database, and the outcome measures.

Materials and Methods {#sec13}
=====================

This review was conducted in accordance with a protocol developed and registered *a priori* (International Prospective Register of Systematic Reviews ID: CRD42016048466). We selected studies that performed a validation of ART population data, which were based on comparison of at least two data sources (health administrative or registry databases, chart reabstraction, self-reported questionnaires). Large administrative or registry databases were defined as those collecting data routinely without an *a priori* research question. We included studies that validated specific data elements or variables (e.g. diagnoses and treatments), case-finding algorithms within fertility databases or registries, or linkage studies between two or more databases that include a fertility registry. In this setting, a data element or variable could include (but was not limited to) diagnosis, treatment, and patient characteristic. Case-finding algorithms were defined as combinations of data elements used to identify a patient population. Linkage studies were defined as studies that used two databases that are joined together to identify or create a study population. The outcomes of interest were measures of diagnostic validity including sensitivity, specificity, PPV, negative predictive value (NPV), likelihood ratio, kappa coefficient, area under the receiver operating characteristic curve or c-statistic, accuracy, or agreement of the selected data elements. Only full-text articles published in English were considered.

The search strategy was developed with the aid of an information specialist with expertise in clinical research, adapted from previous systematic reviews ([@ref4]; [@ref55]). Electronic bibliographic databases, specifically Medline, Embase, and CINAHL, were searched using specific vocabulary and MeSH keywords (see [Supplementary Data 1](#sup1){ref-type="supplementary-material"} for Medline search strategy). Reference lists of all included articles and relevant systematic reviews were screened to identify additional studies. Web pages for major international fertility surveillance systems were searched to account for validation activities presented within surveillance reports, which are typically not indexed in bibliographic databases. We also contacted these surveillance programs to request reports that were not publicly available. These programs included <https://www.belrap.be/Public/Default.aspx?Lg=En> (Belgium), <https://www.sart.org/> (USA), <https://www.asrm.org/about-us/contact-us/> (American Society of Reproductive Medicine), <https://npesu.unsw.edu.au/data-collection/australian-new-zealand-assisted-reproduction-database-anzard> (Australia and New Zealand), <https://www.hfea.gov.uk/> (UK), <https://www.eshre.eu/Home/Contact-us.aspx> (ESHRE), and <https://www.icmr.gov.in/icmrnews/art/contact_us.htm> (India). Citations were imported into EndNote and managed within Covidence ([www.covidence.org](http://www.covidence.org)). This process was recorded using the preferred reporting items for systematic reviews and meta-analysis (PRISMA) flow diagram ([@ref41]). We performed the final search on 6 October 2016. As validating the dataset or part of the dataset is often a secondary objective of studies using routinely collected data, our search strategy could not capture all relevant validation studies. For example, investigators performing a cohort or case-control study involving a specific diagnosis or treatment may validate that data element prior to its use. While that diagnosis or treatment may be relevant to an infertility population, these studies would not be identified as validation studies and thus would not be included.

Screening was performed in two steps by two independent reviewers (V.B. and M.R.) using the eligibility criteria. Title and abstract screening was performed initially, followed by full-text screening. Disagreements were resolved by consensus or through consultation with a senior expert where consensus could not be reached. Reasons for excluding studies in the full-text screening step were documented.

We extracted data from each included study on country of origin, year of publication, number of clinics involved, number of treatment records, sample size calculation, variables or algorithms used, method of validation (chart review versus survey of patients versus another validated database), whether datasets were linked, how datasets were linked (probabilistic versus deterministic), prevalence of the variable(s) under investigation estimated both prior to the study from the target population (pre-test prevalence) and from the study population (post-test prevalence), and validation outcome measures (listed above). Two independent reviewers extracted these data (i.e. in duplicate).

We used items from previously published reporting guidelines for validation studies as a guide to evaluate whether the included studies used rigorous methodology to conduct their validation ([@ref4]). This checklist was implemented by two independent reviewers. We made a post-hoc decision after protocol registration to adapt the quality assessment tools used by two previously published systematic reviews to assess both reporting and quality of studies ([@ref4]; [@ref22]). All results were synthesized qualitatively.

Results {#sec14}
=======

The electronic search yielded 1074 citations after removing duplicates. Upon applying the inclusion and exclusion criteria, we identified 65 studies for full-text screening after title and abstract screening. Seven additional studies were identified for full-text screening after reviewing the references of pertinent articles and searching web pages. Of these 72 studies, 53 did not meet inclusion criteria for various reasons including wrong study design, comparator, or patient population (details can be found in [Supplementary Data 2](#sup1){ref-type="supplementary-material"}). Nineteen studies were included for final analysis ([Fig. 1](#f1){ref-type="fig"}), representing the USA ([@ref62]; [@ref42]; [@ref70], [@ref69], [@ref10], [@ref9]; [@ref15]; [@ref31]; [@ref34]; [@ref13]; [@ref37]; [@ref58], [@ref59]), Finland ([@ref25]; [@ref21]), Denmark ([@ref29]), the Netherlands ([@ref44]), Israel ([@ref50]), and the UK ([@ref68]). Of these studies, four did not use any reference standard ([@ref25]; [@ref21]; [@ref62]; [@ref68]), and the reference was poorly described in two studies ([@ref42]; [@ref50]) ([Table I](#TB1){ref-type="table"}). Two studies used medical records to validate a fertility database ([@ref42]; [@ref13]), seven studies used an IVF registry as the reference standard to validate either vital records or maternal questionnaires ([@ref29]; [@ref69]; [@ref68]; [@ref15]; [@ref34]; [@ref9]; [@ref37]), one study utilized maternal report as the reference standard for validation ([@ref10]), and three studies used vital records (birth and death certificates) as the reference standard ([@ref44]; [@ref31]; [@ref58]). Finally, one study used both IVF registries and vital records as the reference standard depending on the data element validated ([@ref59]).

![Preferred reporting items for systematic reviews and meta-analysis flow diagram.](hoz010f1){#f1}

###### 

Descriptive characteristics of included studies.

  **Authors**                                  **Year**   **Country**   **Data source being validated**                                                        **Reference standard**                                                           **Population**                                                                                                                                                                                                                          **Sample size**
  -------------------------------------------- ---------- ------------- -------------------------------------------------------------------------------------- -------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- -----------------
  Buck Louis GM and Druschel C                 2015       USA           Questionnaire (Upstate New York Infant Development Screening Program Study)            IVF registry (SART CORS)                                                         Mothers who had live births in Upstate New York between July 2008 and May 2010 in whom \`Infertility treatment' was checked on birth certificate and multiple births matched to singleton infants whose treatment box was not checked   5034
  Buck Louis GM and Hediger ML                 2014       USA           Administrative database (Perinatal Data System)                                        Questionnaire                                                                    Mothers who had live births in Upstate New York between July 2008 and May 2010 in whom \`Infertility treatment' was checked on birth certificate and multiple births matched to singleton infants whose treatment box was not checked   4989
  Centers for Disease Control and Prevention   2016       USA           Fertility database (SART)                                                              Medical record                                                                   ART cycle data from 458 fertility clinics in the US during the 2014 cycle year. A random selection of 34 clinics were selected                                                                                                          1996
  Cohen B                                      2014       USA           Administrative database (birth certificates)                                           IVF registry (NASS)                                                              Live births to Florida or Massachusetts resident mothers that occurred in state from March 2004 to December 2006                                                                                                                        856 165
  Gissler M                                    2004       Finland       Administrative database (medical birth record)                                         NA (compared ad hoc IVF research and IVF statistics, no reference standard)      Newborns from fertility treatments from 1996 to 1998                                                                                                                                                                                    176 698
  Hemminki E                                   2003       Finland       Administrative database (Drug Reimbursement Register)                                  Internal examination of data and linkage to Birth Register                       Women exposed to ART between 1996 and 1998                                                                                                                                                                                              24 318
  Hvidtjørn D                                  2009       Denmark       Administrative database                                                                IVF Registry                                                                     Women who participated in the first Danish National Birth Cohort (study) interview with a pregnancy resulting in a live born child between October 2007 and June 2003                                                                   88 151
  Kotelchuck M                                 2014       USA           IVF registry (SART)                                                                    Administrative database (PELL)                                                   Children born to Massachusetts resident women in MA hospitals from July 2004 to December 2008 conceived by ART                                                                                                                          10 138
  Liberman RF                                  2014       USA           Questionnaire (National Birth Defects Prevention Study)                                IVF registry                                                                     Women who completed the NBDPS with in-state deliveries between September 2004 and December 2008                                                                                                                                         77
  Luke B                                       2016       USA           Administrative database (birth certificates)                                           IVF registry                                                                     Live births in Florida, Massachusetts, New York, Pennsylvania, Texas, California, Ohio, and Colorado between 2004 and 2009. IVF cycles from SART CORS were linked to birth certificates.                                                716 103
  Molinaro TA                                  2009       USA           IVF registry                                                                           Medical records                                                                  IVF patients enrolled for other studies at the University of Pennsylvania between December 2003 and June 2006                                                                                                                           590
  Overbeek A                                   2013       Netherlands   Questionnaire (DCOG LATER-VEVO Study---nationwide cohort study)                        Administrative database (Netherlands Perinatal Registry)                         Childhood cancer survivors who achieved pregnancy and their sibling controls                                                                                                                                                            524
  Rosenfeld Y                                  2009a      Israel        IVF reporting system                                                                   Medical record                                                                   Women who receive fertility treatment in the District of Haifa and Western Galilee of the General Health Services                                                                                                                       108
  Stern JE andGopal D                          2016a      USA           IVF registry (SART)                                                                    Administrative database (Massachusetts BDMP Registry)                            ART deliveries from 1 July 2004 to 31 December 2008 in Massachusetts                                                                                                                                                                    9092
  Stern JE and McLain AC                       2016b      USA           Questionnaire (Upstate New York Infant Development Screening Program Study)            SART database for current cycle; Questionnaire for prior treatment information   Mothers who participated in Upstate KIDS Study linked with SART CORS                                                                                                                                                                    617
  Sunderam S                                   2006       USA           Administrative database                                                                IVF registry                                                                     Infants born in 1997 and 1998 in MA, RI, NH, CT to MA-resident mothers who used ART clinics in MA or RI                                                                                                                                 2703
  Williams CL                                  2013       UK            Administrative database (National Registry of Childhood Tumours)                       IVF registry (HFEA)                                                              Children born between 1 January 1992 and 31 December 2008                                                                                                                                                                               106 013
  Zhang Y                                      2012       USA           Administrative database                                                                IVF registry (NASS)                                                              Live births to MA-resident mothers that occurred in MA during 1997-2000                                                                                                                                                                 6139
  Zhang Z                                      2010       USA           Administrative database (Massachusetts Registry of Vital Records and Statistics-MBC)   IVF registry (NASS)                                                              Live births to MA-resident mothers that occurred in MA during 1997--2000                                                                                                                                                                5190

BDMP, Birth Defects Monitoring Program; NASS, National ART Surveillance System; NBDP, National Birth Defects Prevention; NBPDS, National Birth Defects Prevention Study; PELL, Pregnancy to Early Life Longitudinal data system; SART CORS, Society for Assisted Reproductive Technology Clinical Outcomes Reporting System.

Four studies validated method of conception from birth registries ([@ref21]; [@ref70]; [@ref15]; [@ref37]), two validated diagnoses or treatment variables within the fertility database ([@ref42]; [@ref13]), one study created an algorithm to identify a patient population ([@ref25]), and four studies validated linkage algorithms between a fertility and a second administrative database ([@ref62]; [@ref69]; [@ref68]; [@ref31]).

Sensitivity was the most commonly reported validation measure. Twelve studies reported sensitivity ([@ref29]; [@ref70], [@ref69]; [@ref44]; [@ref10], [@ref9]; [@ref15]; [@ref31]; [@ref34]; [@ref37]; [@ref58], [@ref59]), nine reported specificity ([@ref29]; [@ref70]; [@ref44]; [@ref10], [@ref9]; [@ref15]; [@ref31]; [@ref34]; [@ref37]), six reported PPV ([@ref29]; [@ref70]; [@ref44]; [@ref15]; [@ref31]; [@ref9]), one reported NPV ([@ref9]), five reported the Kappa coefficient ([@ref21]; [@ref44]; [@ref10]; [@ref31]; [@ref58]), and seven reported percentage agreement ([@ref21]; [@ref29]; [@ref69]; [@ref44]; [@ref10]; [@ref58], [@ref59]) ([Table II](#TB2){ref-type="table"}). The data quality measures are presented in [Supplementary Data 3](#sup1){ref-type="supplementary-material"}. Only three studies reported four or more measures of validation ([@ref29]; [@ref10], [@ref9]). Nine studies presented 95% CIs with the estimates ([@ref21]; [@ref70], [@ref69]; [@ref44]; [@ref15]; [@ref34]; [@ref9]; [@ref13]; [@ref58]), of which five reported CIs for all estimates ([@ref69]; [@ref15]; [@ref34]; [@ref9]; [@ref13]).

###### 

Summary of reported validity measures.

  Study       Sensitivity   Specificity   PPV     NPV     Kappa   \% Agreement   ICC   AUC/c-statistic   Likelihood ratios   Four or more measures of validity   Number of measures   95% CI
  ----------- ------------- ------------- ------- ------- ------- -------------- ----- ----------------- ------------------- ----------------------------------- -------------------- --------
  [@ref9])    10/10         10/10         10/10   10/10   No      No             No    No                No                  10/10                               4                    10/10
  [@ref10])   1/4           1/4           No      No      1/4     4/4            No    No                No                  1/4                                 4                    0/4
  [@ref13])   No            No            No      No      No      No             No    No                No                  No                                  1                    18/18
  [@ref15])   2/2           2/2           2/2     No      No      No             No    No                No                  No                                  3                    2/2
  [@ref21])   No            No            No      No      1/2     2/2            No    No                No                  No                                  2                    1/2
  [@ref25])   No            No            No      No      No      No             No    No                No                  No                                  0                    NA
  [@ref29])   3/3           3/3           3/3     No      No      3/3            No    No                No                  3/3                                 4                    0/3
  [@ref31])   3/3           1/3           3/3     No      3/3     No             No    No                No                  No                                  4                    0/3
  [@ref34])   5/5           5/5           No      No      No      No             No    No                No                  No                                  2                    5/5
  [@ref37])   1/1           1/1           No      No      No      No             No    No                No                  No                                  2                    No
  [@ref42])   No            No            No      No      No      No             No    No                No                  No                                  0                    NA
  [@ref44])   10/26         10/26         10/26   No      16/26   16/26          No    No                No                  No                                  4                    16/26
  [@ref51])   No            No            No      No      No      No             No    No                No                  No                                  2                    No
  [@ref58])   6/11          No            No      No      2/11    2/11           No    No                No                  No                                  3                    6/11
  [@ref59])   13/13         No            No      No      No      3/13           No    No                No                  No                                  5                    No
  [@ref62])   No            No            No      No      No      No             No    No                No                  No                                  0                    NA
  [@ref68])   No            No            No      No      No      No             No    No                No                  No                                  1                    No
  [@ref69])   1/1           No            No      No      No      No             No    No                No                  No                                  2                    1/2
  [@ref70])   1/1           1/1           1/1     No      No      No             No    No                No                  No                                  3                    3/3

AUC, area under the curve; ICC, intraclass correlation coefficient; NPV, negative predictive value; PPV, positive predictive value.

Numerator: number of validated variables; denominator: total number of variables considered for validation in each study.

The elements of data quality are summarized in [Tables III](#TB3){ref-type="table"} and [IV](#TB4){ref-type="table"}. Sixteen studies (84.2%) adequately described their data source, and all but one described the type of patient records from which data were extracted ([@ref50]). The studies predominantly described inclusion and exclusion criteria and their methods for determining the validity of the data. Fifteen studies adequately described their method of patient sampling while 14 studies sampled the entire population in the database ([@ref25]; [@ref62]; [@ref29]; [@ref70], [@ref69]; [@ref68]; [@ref44]; [@ref10], [@ref9]; [@ref15]; [@ref31]; [@ref34]; [@ref37]; [@ref58]); one study performed a random sampling strategy ([@ref13]). Only one group performed their study using an *a priori* sample size ([@ref13]), and none provided statistical justification for their sample size.

###### 

Reporting quality of methodology of included studies.

  **Methods**                                                                                                                                                              **Frequency**   **%**
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------ --------------- -------
  Describes the data source                                                                                                                                                                
   Yes                                                                                                                                                                     16/19           84.2
   Incomplete                                                                                                                                                              2/19            10.5
   Unclear                                                                                                                                                                 1/19            5.3
  Describes type of records (inpatient, outpatient, linked records)                                                                                                                        
   Yes                                                                                                                                                                     18/19           94.7
   Unclear                                                                                                                                                                 1/19            5.3
  Describes setting and locations where data were collected                                                                                                                                
   Yes                                                                                                                                                                     18/19           94.7
   Incomplete                                                                                                                                                              1/19            5.3
  Reports a priori sample size                                                                                                                                                             
   Yes                                                                                                                                                                     1/19            5.3
  Provides statistical justification for the sample size                                                                                                                                   
   Yes                                                                                                                                                                     0/19            0.0
  Describe recruitment procedure of validation cohort (from a database, based on diagnostic codes)                                                                                         
   Yes                                                                                                                                                                     17/19           89.5
   Unclear                                                                                                                                                                 2/19            10.5
  Describe patient sampling (Random, consecutive, all)                                                                                                                                     
   Random sampling                                                                                                                                                         1/19            5.3
   All                                                                                                                                                                     14/19           73.7
   Unclear                                                                                                                                                                 2/19            10.5
   Incomplete                                                                                                                                                              2/19            10.5
  Describe how participants were chosen for data collection and analysis                                                                                                                   
   Yes                                                                                                                                                                     15/19           78.9
   Unclear                                                                                                                                                                 2/19            10.5
  Describes inclusion/exclusion criteria                                                                                                                                                   
   Yes                                                                                                                                                                     14/19           73.7
   Incomplete                                                                                                                                                              1/19            5.3
  Describes who identified patients (for patients identified from medical records)                                                                                                         
   Yes                                                                                                                                                                     1/19            5.3
   Incomplete                                                                                                                                                              1/19            5.3
  Describes who collected data                                                                                                                                                             
   Yes                                                                                                                                                                     3/19            15.8
  Describes use of a priori data collection form                                                                                                                                           
   Yes                                                                                                                                                                     13/19           68.4
   Unclear                                                                                                                                                                 1/19            5.3
  Use of a split sample or an independent sample (revalidation using a separate cohort)                                                                                                    
   Yes                                                                                                                                                                     1/19            5.3
  Describes the reference standard                                                                                                                                                         
   Yes                                                                                                                                                                     13/17           76.5
  Reports the number of persons reading the reference standard                                                                                                                             
   Yes                                                                                                                                                                     2/17            11.8
  Describes the training or expertise of persons reading reference standard                                                                                                                
   Yes                                                                                                                                                                     1/17            5.9
  Readers of the reference standard were blinded to the results of the classification by routinely collected data for that patient (reference standard: medical records)                   
   Yes                                                                                                                                                                     1/17            5.9
  Reports a measure of concordance if \>1 persons reading the reference standard                                                                                                           
   Yes                                                                                                                                                                     0/17            0.0
  Describes the linkage procedure, if done (probabilistic/deterministic)                                                                                                                   
   Yes                                                                                                                                                                     8/15            50.0
   Incomplete                                                                                                                                                              6/15            37.5
  Describes the methods of linkage quality evaluation                                                                                                                                      
   Yes                                                                                                                                                                     7/15            46.7
   Incomplete                                                                                                                                                              2/15            13.3
  Describes explicit methods for calculating or comparing measures of accuracy and statistical methods used to quantify uncertainty                                                        
   Yes                                                                                                                                                                     13/19           68.4

###### 

Reporting quality of the results of included studies.

                                                                                                     Frequency   \%
  -------------------------------------------------------------------------------------------------- ----------- ------
  Reports the number of participants satisfying the inclusion/exclusion criteria                                 
   Yes                                                                                               13/18       68.4
   Incomplete                                                                                        1/18        5.6
  Describes the characteristics of misclassified patients (false positives and/or false negatives)               
   Yes                                                                                               13/18       68.4
   Unclear                                                                                           2/18        11.1
  Provides a study flow diagram                                                                                  
   Yes                                                                                               4/19        21.1
  Reports the number of records unable to link                                                                   
   Yes                                                                                               11/12       91.7
   Incomplete                                                                                        1/12        8.3
  Reports missing medical records or reports the number of patients unwilling to participate                     
   Yes                                                                                               10/19       52.6
  Reports incomplete records                                                                                     
   Yes                                                                                               13/19       68.4
  Presents a cross tabulation of results of the validated source to the reference standard                       
   Yes                                                                                               11/19       57.9
   Incomplete                                                                                        1/19        5.3
  Reports the pretest prevalence in the study sample                                                             
   Yes                                                                                               5/19        26.3
   Incomplete                                                                                        2/19        10.5
  Tests and reports results of multiple algorithms                                                               
   Yes                                                                                               6/15        40.0
  Reports estimates of test reproducibility of the split or independent sample if done                           
   Yes                                                                                               0/19        0.0

Where multiple databases were linked using a common patient identifier, the linkage procedures were adequately described in eight (53.3%) of the studies ([@ref62]; [@ref70], [@ref69]; [@ref68]; [@ref15]; [@ref31]; [@ref58], [@ref59]). The quality of these procedures was described in only seven studies (46.7%) ([@ref25]; [@ref62]; [@ref70], [@ref69]; [@ref68]; [@ref31]; [@ref58]).

The pre-test prevalence of the validated variables was provided in seven studies ([@ref62]; [@ref70]; [@ref10]; [@ref15]; [@ref31]; [@ref34]; [@ref37]) ([Table V](#TB5){ref-type="table"}). The post-test prevalence of these variables was within a 2% range of the pre-test values for four of the studies ([@ref70]; [@ref15]; [@ref31]; [@ref34]); however, in two studies, the post-test prevalence was largely discrepant from pre-test values ([@ref10]; [@ref37]).

###### 

Description of the pre- and post-test prevalence of measured estimates of validity in included studies.

  Study      Prevalence estimate reported   Pre-test prevalence (%)   Post-test prevalence[^\*^](#tblfn1){ref-type="table-fn"}(%)
  ---------- ------------------------------ ------------------------- -------------------------------------------------------------
  [@ref9]    No                             ---                       ---
  [@ref10]   ART conceived infant           1.40                      14.0
  [@ref13]   No                             ---                       ---
  [@ref15]   ART conceived infant           1.40                      0.45
  [@ref21]   No                             ---                       ---
  [@ref25]   No                             ---                       ---
  [@ref29]   No                             ---                       ---
  [@ref31]   ART conceived infant           1.60                      2.72
  [@ref34]   ART conceived infant in MA     4.30                      5.30
  [@ref37]   ART conceived infant           1.70                      9.80
  [@ref42]   No                             ---                       ---
  [@ref44]   No                             ---                       ---
  [@ref51]   No                             ---                       ---
  [@ref58]   Incomplete                     ---                       ---
  [@ref59]   No                             ---                       ---
  [@ref62]   Yes                            3.00                      ---
  [@ref68]   No                             ---                       ---
  [@ref69]   No                             ---                       ---
  [@ref70]   ART Live birth deliveries      3.00                      1.70

^\*^Based on reference standard.

Discussion {#sec15}
==========

This study demonstrates that there is a paucity of the literature on the validation of data elements within fertility databases and registries. There were numerous studies that validated ART information derived from maternal report or birth and death certificates by comparing those data to the reference standard of a fertility registry; however, we only identified one study that assessed the validity of a fertility registry by comparing data elements from the database to the reference standard of the patient record ([@ref13]). Furthermore, only seven studies published the baseline prevalence of the data element being validated ([@ref62]; [@ref70]; [@ref10]; [@ref15]; [@ref31]; [@ref34]; [@ref37]), of which only four studies' sample prevalence approximated that of the population ([@ref10]; [@ref37]).

There are three commonly cited validation study designs: ecological studies, reabstraction studies, and gold standard studies ([@ref65]). Ecological studies compare measures of disease prevalence in the database to those obtained from more reliable methods, like those published elsewhere. Reabstraction studies compare the database variable or element to the medical record. Finally, gold standard studies compare the database variable to a case definition, either based on clinical or laboratory values or clinical consensus ([@ref65]).

[@ref25]) and [@ref21]) both performed ecological studies using national statistics. [@ref25]) and [@ref21]) created a case-finding algorithm using data from a drug reimbursement register and a physician examination and intervention register to identify an infertility population in Finland. They subsequently compared these data to national statistics to validate their algorithm. [@ref21]) compared prevalence estimates both from a birth registry and from aggregate IVF statistics to estimates generated from Hemminki's study to assess the completeness and validity of these routinely collected data sources. Firstly, these reference standards rely on the accuracy of the national statistics, which were not established and should not be implicitly assumed. Secondly, as the comparison is based on aggregate data rather than patient-level data, identifying specific differences and agreements is impossible.

Of the 19 studies included in our review, only 2 used the medical record as the reference standard ([@ref42]; [@ref13]), and only 1 presented measures of validation ([@ref13]). The others used either another database or patient report as the reference. [@ref42]) attempted to validate diagnosis variables in The Society of American Reproductive Technologies (SART) using case definitions based on clinical values in the patients' charts rather than relying on the expertise of clinicians. They did not report their measures of validity, making it challenging to determine if this method is superior. Using objective measures, such as laboratory tests and strict diagnostic criteria, for validation compared to documentation may be more reliable, though such approaches were not identified by our review of ART validation studies.

The study performed by SART assessed multiple patient variables at one time, comparing SART data to patient charts ([@ref13]). However, due to the presentation of discrepancy rates without other important measures of validity, such as sensitivity, kappa coefficients, or PPVs, it is difficult to determine how reliable these data are. A subgroup evaluation by the size of the clinic or geography would be useful to investigate whether specific variables are largely problematic or if there is an issue at a specific clinic.

A Canadian study investigating the validity of diagnostic codes in 10 major hospitals found that the sensitivity and specificity were highly dependent on the hospital, where some had a high accuracy and others demonstrated poor sensitivity ([@ref30]). Clinics may have specific expertise with respect to their patient populations, and the prevalence of certain conditions or treatments may vary based on health care provider. Predictive tests (PPV, likelihood ratios) are highly dependent on the baseline prevalence of the specific treatment or disease ([@ref2]). Furthermore, in certain cases, the sensitivity and specificity may vary with the prevalence ([@ref8]). While the accuracy of those records would not necessarily be influenced, the metrics such as PPV, NPV, and sensitivity will be affected. Only four of the included studies presented post-test prevalence estimates that approximated the reported pre-test prevalence; it, therefore, puts into question the degree of bias in the estimates presented. As such, it is essential to describe both the source of data and prevalence of the variable of interest to adequately interpret the results.

There is insufficient documentation in the literature with respect to how national fertility registries are validating their databases. SART publishes a publicly available report on an annual basis indicating which variables are discrepant between the medical chart and the database ([@ref13]). According to ICMART's world report, there were 61 countries that submitted nationwide ART data for surveillance ([@ref18]). Unfortunately, none of the other national databases have generated such reports or have made them easily accessible. The Human Fertilisation and Embryology Authority in the UK, Australian & New Zealand Assisted Reproduction Database (ANZARD), and the Belgian Register for Assisted Procreation endorse strict adherence to quality assurance practices; however, no reports were available describing their data-validation processes (written communication with Belgium and ANZARD). As all stakeholders, including patients, health care practitioners, researchers, and policy makers, rely on these data to understand the implications of fertility treatments, including the prevalence of disease, practice patterns, and complications and outcomes of ART, it is essential that these reports are made publicly available ([@ref11]; [@ref14]; [@ref12]; [@ref23]; [@ref28]).

It is clear from this review that databases are audited, but tracking that process and determining which data elements are reliable are challenging. Therefore, a gold standard from this source should not be implicitly accepted. More studies investigating the accuracy of routinely collected data in local or national registries need to be performed and published, with adherence to reporting guidelines. Upon demonstration of data validity, research can be performed utilizing these databases with measures to reduce bias. Finally, patient report is subject to recall bias, particularly as increasing time has passed from the event to the survey ([@ref33]).

Our review has several limitations. We restricted our inclusion criteria to published reports in English. As many of the internal processes are likely to occur in the primary language of the registry or organization, it is possible that we were unable to capture validation processes from registries. A comprehensive search on the internet did not yield any results, even in other languages, however. Moreover, only four studies were excluded from our database search due to language restriction ([@ref35]; [@ref51]; [@ref3]; [@ref46]). Our study was also limited by the search strategy developed for Medline, Embase, and CINAHL. While the strategy was quite general for routinely collected databases, the list was not exhaustive for specific diagnoses relevant to infertility. Consequently, it is probable that other published studies were not captured in our review.

In spite of these limitations, our study is strengthened by the systematic and comprehensive approach to searching the articles and analyzing the measures of validity. This is the first study to our knowledge to assess the utility of validation tools for fertility registries. Although many of these reports were not published in indexed bibliographic databases, numerous attempts were made to contact ART surveillance database managers in the UK, Denmark, Belgium, Australia, New Zealand, and the USA to obtain unpublished or ad hoc reports on data maintenance and quality assurance.

This review highlights an important gap in the field of fertility research where the validation of widely utilized databases has not been well described. Big data are increasingly used for research, quality assurance, and policy; therefore, the accuracy of these data is essential. Furthermore, during the validation process, the prevalence of the variables and the statistical estimates need to be adequately measured and compared to the prevalence from the drawn study population. This would allow the reader to assess the generalizability of the study population to the general population. As the prevalence of the condition varies based on health care provider or geographic location, so will these measures. Future studies need to be conducted and published using rigorous methodology that will allow for greater transparency and accuracy of research within this rapidly evolving field of medicine and research.
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